[
    [
        {
            "time": "2018-01-02",
            "original_text": "5 Top Non-Tech Earnings Charts",
            "features": {
                "keywords": [
                    "Non-Tech",
                    "Earnings",
                    "Charts"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "non-tech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "5 Top Non-Tech Earnings Charts",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-03-15",
            "original_text": "Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review",
            "features": {
                "keywords": [
                    "Alkermes",
                    "NDA",
                    "FDA",
                    "Review"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Alkermes' (ALKS) NDA for ALKS 3831 Accepted by FDA for Review",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-01-25",
            "original_text": "Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",
            "features": {
                "keywords": [
                    "Drug",
                    "Biotech",
                    "Stock",
                    "Earnings",
                    "BIIB",
                    "ALXN"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-04-24",
            "original_text": "Eli Lilly Reports Earnings Tomorrow. Here’s What to Expect.",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Earnings",
                    "Tomorrow",
                    "Expect"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly Reports Earnings Tomorrow. Here’s What to Expect.",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-05-10",
            "original_text": "CVS to offer diabetes drugs at no out-of-pocket costs for PBM members",
            "features": {
                "keywords": [
                    "CVS",
                    "diabetes",
                    "drugs",
                    "out-of-pocket",
                    "PBM",
                    "members"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CVS to offer diabetes drugs at no out-of-pocket costs for PBM members",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-06-20",
            "original_text": "Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application",
            "features": {
                "keywords": [
                    "Lilly",
                    "FDA",
                    "Priority",
                    "Review",
                    "Selpercatinib",
                    "New Drug Application"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]